<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle18
{mso-style-type:personal;
font-family:Palatino;
color:windowtext;
font-weight:normal;
font-style:normal;}
span.EmailStyle19
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:492375208;
mso-list-template-ids:-2053440300;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1
{mso-list-id:959720844;
mso-list-template-ids:328891592;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-015.html__;!!PhOWcWs!npPqBbW4Awq5UIt1u0Tj9dPg8baW0NPlvlqtv18A4211m4rHo4Oa-9Hzhj3Zb51vW_QvmGl8emCVs1M6XgA$" target="_blank">Patient-oriented Research to Mitigate Health Disparities and Lessen the Burden of Chronic Diseases
Within the Mission of NIDDK (R01 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement invites applications to conduct patient-oriented clinical research studies designed to develop strategies to mitigate health disparities in people
with one or more chronic diseases or conditions within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Populations of interest include those disproportionately burdened with multiple chronic conditions and/or disparities
in social, behavioral and/or biological risk factors. Only studies that involve interaction with human participants will be considered appropriate for this FOA.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due May 22, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: May 11.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.amgenscientificgrants.com/migraine/index.html__;!!PhOWcWs!npPqBbW4Awq5UIt1u0Tj9dPg8baW0NPlvlqtv18A4211m4rHo4Oa-9Hzhj3Zb51vW_QvmGl8emCVP9ZRtCY$" target="_blank">Amgen Foundation: Migraine Research</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Amgen's Competitive Grant Program in Migraine Research will provide an opportunity for early career investigators in the United States to compete for individual grants of US$50,000–150,000
for novel research proposals that seek to advance the medical knowledge of migraine. The program is limited to proposals from early career investigators (interns, residents, headache medicine fellows, and healthcare professionals within 5 years of completion
of training) based in the United States and requires a letter of recommendation from their department or laboratory head.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Specific predefined areas of research eligible for a Competitive Grant Program in Migraine Research award include:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l0 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Non-interventional clinical research with a focus on early diagnosis and treatment, epidemiology, and Patient Reported Outcomes (PRO)/Quality of Life (QoL)
measures.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Biomarkers for diagnosis and prognosis.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Preclinical research focused on mechanism of disease (non-calcitonin gene-related peptide [CGRP]- and non-pituitary adenylate cyclase-activating polypeptide
[PACAP]-related).<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due May 22, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: May 11.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-138.html__;!!PhOWcWs!npPqBbW4Awq5UIt1u0Tj9dPg8baW0NPlvlqtv18A4211m4rHo4Oa-9Hzhj3Zb51vW_QvmGl8emCV8AXoV2c$" target="_blank">Center of Excellence for Research on Complementary and Integrative Health (P01 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) encourages the submission of applications requiring multi-project, synergistic collaborations blending multiple research approaches from outstanding
multidisciplinary research teams. This Center of Excellence for Research on Complementary and Integrative Health (CERCIH) program is designed to support three or more highly meritorious projects that can offer significant scientific advantages and “synergy”
that could not be achieved by supporting the same projects as individual research grants. Each CERCIH must be focused on questions of high relevance to the mission of NCCIH and high research priority based on the current Strategic Plan. Applications in response
to this FOA may propose to involve human participants in mechanistic studies, but this FOA will not support clinical trials of efficacy or effectiveness.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires May 26, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for May 25, 2020 standard date: May 12.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Congressionally Directed Medical Research Programs<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://cdmrp.army.mil/funding/mbrp__;!!PhOWcWs!npPqBbW4Awq5UIt1u0Tj9dPg8baW0NPlvlqtv18A4211m4rHo4Oa-9Hzhj3Zb51vW_QvmGl8emCVOlD2-gw$" target="_blank">Military Burn Research Program</a><br>
<b>Clinical Translational Research Award</b><br>
Pre-application (prepropsal): May 15, 2020. Invited full application: August 20, 2020.
<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for pre-application: May 4.</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://cdmrp.army.mil/funding/prorp__;!!PhOWcWs!npPqBbW4Awq5UIt1u0Tj9dPg8baW0NPlvlqtv18A4211m4rHo4Oa-9Hzhj3Zb51vW_QvmGl8emCVdDMkAjY$" target="_blank">Peer Reviewed Orthopaedic Research Program</a><br>
<b>Applied Research Award</b><br>
Pre-application (preproposal): May 27, 2020. Application: September 10, 2020. <br>
<b>Clinical Trial Award</b><br>
Pre-application (preproposal): May 27, 2020. Application: September 10, 2020. <o:p>
</o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for pre-application: May 18.</span></b><span style="font-size:12.0pt;font-family:Palatino"><br>
<b>Clinical Translational Research Award</b><br>
Pre-application: April 15, 2020. Invited full application: July 16, 2020. <o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for pre-application: April 2.</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://cdmrp.army.mil/funding/prorp__;!!PhOWcWs!npPqBbW4Awq5UIt1u0Tj9dPg8baW0NPlvlqtv18A4211m4rHo4Oa-9Hzhj3Zb51vW_QvmGl8emCVdDMkAjY$" target="_blank">Prostate Cancer Research Program</a><br>
<b>Early Investigator Research Award</b><br>
Pre-application (letter of intent): June 4, 2020. Confidential letters of recommendation: June 23, 2020. Application: June 18, 2020.
<br>
<b>Physician Research Award</b><br>
Pre-application (letter of intent): June 4, 2020. Confidential letters of recommendation: June 23, 2020. Application: June 18, 2020.
<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for pre-application: May 26.<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://cdmrp.army.mil/funding/scirp__;!!PhOWcWs!npPqBbW4Awq5UIt1u0Tj9dPg8baW0NPlvlqtv18A4211m4rHo4Oa-9Hzhj3Zb51vW_QvmGl8emCVGkMwlrw$" target="_blank">Spinal Cord Injury Research Program</a><br>
<b>Clinical Trial Award</b><br>
Pre-application (preproposal): May 21, 2020. Application: August 25, 2020.<br>
<b>Translational Research Award</b><br>
Pre-application (preproposal): May 21, 2020. Application: August 25, 2020.<br>
<b>Investigator Initiated Research Award</b><br>
Pre-application (preproposal): May 21, 2020. Application: August 25, 2020.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for pre-application: May 11.</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://cdmrp.army.mil/funding/tbdrp.aspx__;!!PhOWcWs!npPqBbW4Awq5UIt1u0Tj9dPg8baW0NPlvlqtv18A4211m4rHo4Oa-9Hzhj3Zb51vW_QvmGl8emCVsegwyf8$" target="_blank">Tick-Borne Disease Research Program</a><br>
<b>Career Development Award</b><br>
Pre-application (preproposal): May 27, 2020. Invited full application: August 27, 2020.<br>
<b>Idea Award</b><br>
Pre-application (preproposal): May 27, 2020. Invited full application: August 27, 2020.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for pre-application: May 18.</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PA-18-932.html__;!!PhOWcWs!npPqBbW4Awq5UIt1u0Tj9dPg8baW0NPlvlqtv18A4211m4rHo4Oa-9Hzhj3Zb51vW_QvmGl8emCVKnexCHA$" target="_blank">Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations (R01 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement invites applications that seek to understand strategies to reduce disparities in the uptake of evidence-based screening (e.g., screening recommendations
proven to be effective based on rigorous systematic review of scientific evidence by authoritative committees) across the adult lifespan. In this program announcement, screening is defined as a preventive service focused on detection of an undiagnosed disease
in asymptomatic populations. Research supported by this initiative should enhance the screening process related to use: (1) in diverse populations, (2) in diverse clinical and community settings, and/or (3) with traditional, non-traditional and/or allied health
care providers.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Due January 8, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for June 5, 2020 standard date: May 26.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-140.html__;!!PhOWcWs!npPqBbW4Awq5UIt1u0Tj9dPg8baW0NPlvlqtv18A4211m4rHo4Oa-9Hzhj3Zb51vW_QvmGl8emCV1t7uduk$" target="_blank">Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical
Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement is to promote development of innovative, enabling tools and technologies in the areas of kidney, urologic, and hematologic diseases.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires May 8, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for June 16, 2020 standard date: June 3.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Novel Synthetic Nucleic Acid Technology Development (R21 / R01) (Clinical Trial not allowed)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-015.html__;!!PhOWcWs!npPqBbW4Awq5UIt1u0Tj9dPg8baW0NPlvlqtv18A4211m4rHo4Oa-9Hzhj3Zb51vW_QvmGl8emCVbrk-ALU$" target="_blank">R21</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-014.html__;!!PhOWcWs!npPqBbW4Awq5UIt1u0Tj9dPg8baW0NPlvlqtv18A4211m4rHo4Oa-9Hzhj3Zb51vW_QvmGl8emCVdFApl9k$" target="_blank">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">These Funding Opportunity Announcements (FOA) solicit grant applications to develop novel technologies that will enable substantive (no less than one order of magnitude) improvement in
synthetic nucleic acids. The goal is to improve the quality, capabilities, and efficiency of nucleic acid synthesis and synthetic constructs at reasonable and decreased costs. Applicants may propose to develop novel complete synthesis and/or synthetic constructs
systems, investigate challenges underlying key novel system components, or propose substantive improvements of at least an order of magnitude improvement to existing systems. Exploration of methods other than those currently in use is highly encouraged.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due June 24, 2020; February 1, 2021; October 1, 2021; and June 24, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for June 24, 2020 deadline: June 11.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-19-099.html__;!!PhOWcWs!npPqBbW4Awq5UIt1u0Tj9dPg8baW0NPlvlqtv18A4211m4rHo4Oa-9Hzhj3Zb51vW_QvmGl8emCV4lZtu60$" target="_blank">Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative Innovation
Award (U01 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Note:</span></b><span style="font-size:12.0pt;font-family:Palatino"> For this U01, “limited competition” means (1) only institutions with a CTSA can apply, and (2) the application must
include investigators from three (or more) program hub institutions. The UF-FSU CTSA is a single hub. The Clinical and Translational Science Award (CTSA) Program Collaborative Innovation Award (CCIA) supports collaborative research activities that develop
innovative solutions that will improve the efficiency, quality and impact of turning laboratory, clinic and community observations into interventions that improve the health of individuals and the public. This funding opportunity announcement (FOA) will support
investigators from three or more CTSA Program hub institutions (<a href="https://urldefense.com/v3/__https://projectreporter.nih.gov/Reporter_Viewsh.cfm?sl=15EEC10C4A89CEDF7598B8961CAA4A01A2FFCEB861BF__;!!PhOWcWs!npPqBbW4Awq5UIt1u0Tj9dPg8baW0NPlvlqtv18A4211m4rHo4Oa-9Hzhj3Zb51vW_QvmGl8emCVFaFCk3g$">see current UL1 awardees</a>) to either: 1) form new collaborations, or to 2) significantly
expand the scientific scope of existing collaborations, or to 3) engage new collaborators in pre-existing collaborations to solve a translational science problem no one hub can solve alone, or disseminate a solution to a translational science problem developed
at one hub to other hubs, in so doing testing its robustness to different hub environments and structures and adapting it for further dissemination within outside the CTSA Program consortium if appropriate.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due July 10, 2020; November 9, 2020; March 8, 2021; July 9, 2021; and November 9, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for July 10, 2020 deadline: June 29.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-19-100.html__;!!PhOWcWs!npPqBbW4Awq5UIt1u0Tj9dPg8baW0NPlvlqtv18A4211m4rHo4Oa-9Hzhj3Zb51vW_QvmGl8emCVPsVrJBc$" target="_blank">Limited Competition: Clinical and Translational Science Award (CTSA) Program: Exploratory Collaborative
Innovation Awards (R21 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Note:</span></b><span style="font-size:12.0pt;font-family:Palatino"> For this U01, “limited competition” means (1) only institutions with a CTSA can apply, and (2) the application must
include investigators from two (or more) program hub institutions. The UF-FSU CTSA is a single hub. The Clinical and Translational Science Award (CTSA) Program Collaborative Innovation Award (CCIA) supports collaborative research activities that develop innovative
solutions that will improve the efficiency, quality and impact of turning laboratory, clinic and community observations into interventions that improve the health of individuals and the public. This funding opportunity announcement (FOA) will support investigators
from two or more CTSA Program hub institutions (<a href="https://urldefense.com/v3/__https://projectreporter.nih.gov/Reporter_Viewsh.cfm?sl=15EEC10C4A89CEDF7598B8961CAA4A01A2FFCEB861BF__;!!PhOWcWs!npPqBbW4Awq5UIt1u0Tj9dPg8baW0NPlvlqtv18A4211m4rHo4Oa-9Hzhj3Zb51vW_QvmGl8emCVFaFCk3g$" target="_blank">see current UL1 awardees</a>) to either: 1) form new collaborations, or to 2) significantly
expand the scientific scope of existing collaborations, or to 3) engage new collaborators in pre- existing collaborations to solve a translational science problem no one hub can solve alone, or disseminate a solution to a translational science problem developed
at one hub to other hubs, in so doing testing its robustness to different hub environments and structures and adapting it for further dissemination within outside the CTSA Program consortium if appropriate.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due July 10, 2020; November 9, 2020; March 8, 2021; July 9, 2021; and November 9, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for July 10, 2020 deadline: June 29.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R21 / R01 Clinical Trial Optional)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/rfa-ca-20-028.html__;!!PhOWcWs!npPqBbW4Awq5UIt1u0Tj9dPg8baW0NPlvlqtv18A4211m4rHo4Oa-9Hzhj3Zb51vW_QvmGl8emCV47VQeZw$" target="_blank">R21</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-027.html__;!!PhOWcWs!npPqBbW4Awq5UIt1u0Tj9dPg8baW0NPlvlqtv18A4211m4rHo4Oa-9Hzhj3Zb51vW_QvmGl8emCVFSv3Q8Y$" target="_blank">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Through these Funding Opportunity Announcements (FOAs), the National Cancer Institute invites applications describing research focused on improving care and health-related quality of life
for childhood, and adolescent, and young adult (AYA) cancer survivors. Specifically, these FOAs solicit mechanistic, observational, and intervention applications that focus on six key domains: (1) disparities in survivor outcomes; (2) barriers to follow-up
care (e.g., access, adherence); (3) impact of familial, socioeconomic, and other environmental factors on survivor outcomes; (4) indicators for long-term follow-up needs related to risk for late effects, recurrence, and subsequent cancers; (5) risk factors
and predictors of late/long-term effects of cancer treatment; and (6) development of targeted interventions to reduce the burden of cancer for pediatric/AYA survivors.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due July 31, 2020 and July 30, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for July 31, 2020 deadline: July 20.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">To search for additional funding opportunities, please visit </span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69"><b><span style="color:red">CoM’s
unofficial funding opportunities blog</span></b></a><b>.</b></span><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
</div>
</body>
</html>